Dizal’s lung cancer drug meets primary goal in phase 3 trial

SHANGHAI - Dizal (SSE:688192) announced today that its phase 3 WU-KONG28 study evaluating ZEGFROVY as first-line treatment for non-small cell lung cancer with EGFR exon 20 insertion mutations met its primary endpoint, according to a press release statement. The biotech company, with a market capitalization of $3.28 billion, has seen its stock decline 30% over the past six months despite revenue surging 123% in the last twelve months as of Q4 2025.